Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities

An abstract of the study by Kunita et al developing novel mouse anti-PDPN mAbs, LpMab-2, LpMab-7, and LpMab-23 using the cancer-specific mAb (CasMab) technology is presented. In the study, mouse-human chimeric anti-PDPN mAbs, chLpMab-2, chLpMab-7, and chLpMab-23 were generated and characterized. The...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2016-12, Vol.69, p.S57-S57
Hauptverfasser:	Kunita, A, Kaneko, M.K, Ogasawara, S, Fukayama, M, Kato, Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticancer properties Antitumor activity Cancer Cytotoxicity Glioblastoma Glycoproteins Hematology, Oncology and Palliative Medicine Lung cancer Mesothelioma Monoclonal antibodies Technology Toxicity Tumor cell lines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	S57
container_issue
container_start_page	S57
container_title	European journal of cancer (1990)
container_volume	69
creator	Kunita, A Kaneko, M.K Ogasawara, S Fukayama, M Kato, Y
description	An abstract of the study by Kunita et al developing novel mouse anti-PDPN mAbs, LpMab-2, LpMab-7, and LpMab-23 using the cancer-specific mAb (CasMab) technology is presented. In the study, mouse-human chimeric anti-PDPN mAbs, chLpMab-2, chLpMab-7, and chLpMab-23 were generated and characterized. They investigated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities of chimeric anti-PDPN mAbs in vitro. Results, novel chimeric anti-PDPN mAbs showed ADCC and CDC activities against CHO/hPDPN, glioblastoma, mesothelioma, or lung cancer cell lines.
doi_str_mv	10.1016/S0959-8049(16)32757-5
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2037440104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0959804916327575</els_id><sourcerecordid>2037440104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1294-dc8c11e3f693c8759f4200c346822fd5ea36b9fb485bd9eb1265ebd194bb77bd3</originalsourceid><addsrcrecordid>eNo9UFtLwzAYDaLgnP4EIeCLPlSTNGmbF2F03mDig_occuuW2ZtJN-m_t1t1Tx8f58Y5AFxidIsRTu7eEWc8yhDl1zi5iUnK0ogdgQnOUh6hjJFjMDlQTsFZCGuEUJpRNAE_-cpV1jsNZd25qG1M05aydjWsZirA1jdmo62Bqoe5DK9Swc7qVd2UzbKHbROCDQGu3HK113ebqvFQ6s5tXdfDrZNwNs_zATMwn-f_iLPhHJwUsgz24u9Owefjw0f-HC3enl7y2SLSmHAaGZ1pjG1cJDzWWcp4QQlCOqZJRkhhmJVxonihaMaU4VZhkjCrDOZUqTRVJp6Cq9F3aPK9saET62bj6yFSEBSnlCKM6MBiI0v7oZK3hWi9q6TvBUZit7HYbyx2A4rh228s2KC7H3V2qLB11gtdutppWX7Z3oZDFBaBCDSa7Dxwsndg8S9234Ud</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2037440104</pqid></control><display><type>article</type><title>Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Kunita, A ; Kaneko, M.K ; Ogasawara, S ; Fukayama, M ; Kato, Y</creator><creatorcontrib>Kunita, A ; Kaneko, M.K ; Ogasawara, S ; Fukayama, M ; Kato, Y</creatorcontrib><description>An abstract of the study by Kunita et al developing novel mouse anti-PDPN mAbs, LpMab-2, LpMab-7, and LpMab-23 using the cancer-specific mAb (CasMab) technology is presented. In the study, mouse-human chimeric anti-PDPN mAbs, chLpMab-2, chLpMab-7, and chLpMab-23 were generated and characterized. They investigated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities of chimeric anti-PDPN mAbs in vitro. Results, novel chimeric anti-PDPN mAbs showed ADCC and CDC activities against CHO/hPDPN, glioblastoma, mesothelioma, or lung cancer cell lines.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(16)32757-5</identifier><language>eng</language><publisher>Oxford: Elsevier Science Ltd</publisher><subject>Anticancer properties ; Antitumor activity ; Cancer ; Cytotoxicity ; Glioblastoma ; Glycoproteins ; Hematology, Oncology and Palliative Medicine ; Lung cancer ; Mesothelioma ; Monoclonal antibodies ; Technology ; Toxicity ; Tumor cell lines</subject><ispartof>European journal of cancer (1990), 2016-12, Vol.69, p.S57-S57</ispartof><rights>Elsevier Ltd</rights><rights>Copyright Elsevier Science Ltd. Dec 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Kunita, A</creatorcontrib><creatorcontrib>Kaneko, M.K</creatorcontrib><creatorcontrib>Ogasawara, S</creatorcontrib><creatorcontrib>Fukayama, M</creatorcontrib><creatorcontrib>Kato, Y</creatorcontrib><title>Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities</title><title>European journal of cancer (1990)</title><description>An abstract of the study by Kunita et al developing novel mouse anti-PDPN mAbs, LpMab-2, LpMab-7, and LpMab-23 using the cancer-specific mAb (CasMab) technology is presented. In the study, mouse-human chimeric anti-PDPN mAbs, chLpMab-2, chLpMab-7, and chLpMab-23 were generated and characterized. They investigated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities of chimeric anti-PDPN mAbs in vitro. Results, novel chimeric anti-PDPN mAbs showed ADCC and CDC activities against CHO/hPDPN, glioblastoma, mesothelioma, or lung cancer cell lines.</description><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Cancer</subject><subject>Cytotoxicity</subject><subject>Glioblastoma</subject><subject>Glycoproteins</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Lung cancer</subject><subject>Mesothelioma</subject><subject>Monoclonal antibodies</subject><subject>Technology</subject><subject>Toxicity</subject><subject>Tumor cell lines</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9UFtLwzAYDaLgnP4EIeCLPlSTNGmbF2F03mDig_occuuW2ZtJN-m_t1t1Tx8f58Y5AFxidIsRTu7eEWc8yhDl1zi5iUnK0ogdgQnOUh6hjJFjMDlQTsFZCGuEUJpRNAE_-cpV1jsNZd25qG1M05aydjWsZirA1jdmo62Bqoe5DK9Swc7qVd2UzbKHbROCDQGu3HK113ebqvFQ6s5tXdfDrZNwNs_zATMwn-f_iLPhHJwUsgz24u9Owefjw0f-HC3enl7y2SLSmHAaGZ1pjG1cJDzWWcp4QQlCOqZJRkhhmJVxonihaMaU4VZhkjCrDOZUqTRVJp6Cq9F3aPK9saET62bj6yFSEBSnlCKM6MBiI0v7oZK3hWi9q6TvBUZit7HYbyx2A4rh228s2KC7H3V2qLB11gtdutppWX7Z3oZDFBaBCDSa7Dxwsndg8S9234Ud</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Kunita, A</creator><creator>Kaneko, M.K</creator><creator>Ogasawara, S</creator><creator>Fukayama, M</creator><creator>Kato, Y</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20161201</creationdate><title>Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities</title><author>Kunita, A ; Kaneko, M.K ; Ogasawara, S ; Fukayama, M ; Kato, Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1294-dc8c11e3f693c8759f4200c346822fd5ea36b9fb485bd9eb1265ebd194bb77bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Cancer</topic><topic>Cytotoxicity</topic><topic>Glioblastoma</topic><topic>Glycoproteins</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Lung cancer</topic><topic>Mesothelioma</topic><topic>Monoclonal antibodies</topic><topic>Technology</topic><topic>Toxicity</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kunita, A</creatorcontrib><creatorcontrib>Kaneko, M.K</creatorcontrib><creatorcontrib>Ogasawara, S</creatorcontrib><creatorcontrib>Fukayama, M</creatorcontrib><creatorcontrib>Kato, Y</creatorcontrib><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kunita, A</au><au>Kaneko, M.K</au><au>Ogasawara, S</au><au>Fukayama, M</au><au>Kato, Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities</atitle><jtitle>European journal of cancer (1990)</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>69</volume><spage>S57</spage><epage>S57</epage><pages>S57-S57</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>An abstract of the study by Kunita et al developing novel mouse anti-PDPN mAbs, LpMab-2, LpMab-7, and LpMab-23 using the cancer-specific mAb (CasMab) technology is presented. In the study, mouse-human chimeric anti-PDPN mAbs, chLpMab-2, chLpMab-7, and chLpMab-23 were generated and characterized. They investigated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities of chimeric anti-PDPN mAbs in vitro. Results, novel chimeric anti-PDPN mAbs showed ADCC and CDC activities against CHO/hPDPN, glioblastoma, mesothelioma, or lung cancer cell lines.</abstract><cop>Oxford</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/S0959-8049(16)32757-5</doi></addata></record>
fulltext	fulltext
identifier	ISSN: 0959-8049
ispartof	European journal of cancer (1990), 2016-12, Vol.69, p.S57-S57
issn	0959-8049 1879-0852
language	eng
recordid	cdi_proquest_journals_2037440104
source	Elsevier ScienceDirect Journals Complete
subjects	Anticancer properties Antitumor activity Cancer Cytotoxicity Glioblastoma Glycoproteins Hematology, Oncology and Palliative Medicine Lung cancer Mesothelioma Monoclonal antibodies Technology Toxicity Tumor cell lines
title	Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A42%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chimeric%20anti-podoplanin%20mAbs%20produced%20by%20CasMab%20technology%20possess%20high%20antitumor%20activity%20via%20ADCC%20and%20CDC%20activities&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Kunita,%20A&rft.date=2016-12-01&rft.volume=69&rft.spage=S57&rft.epage=S57&rft.pages=S57-S57&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(16)32757-5&rft_dat=%3Cproquest_cross%3E2037440104%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2037440104&rft_id=info:pmid/&rft_els_id=1_s2_0_S0959804916327575&rfr_iscdi=true